share_log

Ehave Continues Expansion Of KetaDASH Mobile Psychedelic Service By Providing Licensed Psychotherapists And Registered Nurses

Ehave Continues Expansion Of KetaDASH Mobile Psychedelic Service By Providing Licensed Psychotherapists And Registered Nurses

EHave繼續擴展KetaDASH流動迷幻服務,提供有執照的心理治療師和註冊護士
GlobeNewswire ·  2022/03/03 21:37
  • Agreement with Heally adds doctors, licensed psychotherapists and registered nurses to the KetaDASH platform
  • With the opening of KetaDASH, Ehave builds momentum for the psychedelic renaissance in the mental health field
  • Both the KetaDASH patient and nurse connect to a psychotherapist via Heally's telehealth portal for each treatment session
  • 與Heally達成的協議為KetaDASH平臺增加了醫生、有執照的心理治療師和註冊護士
  • 隨着KetaDASH的開業,eHave為精神健康領域的迷幻復興建立了動力
  • KetaDASH患者和護士在每次治療過程中都會通過Heally的遠程健康門户連接到心理治療師

MIAMI, March 03, 2022 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the "Company"), a leading healthcare services and technology company, announced today it will partner with Heally, the all-in-one platform and electronic medical record (EMR)/telehealth solution for alternative medicine providers, to provide Licensed Psychotherapists And Registered Nurses to its KetaDASH patients. This mobile solution departs from in-person intravenous treatment, as well as unsupervised telehealth models.

邁阿密,2022年3月3日(環球通訊社)-領先的醫療服務和技術公司eHave,Inc.(場外交易代碼:EHVVF)(以下簡稱“公司”)今天宣佈,它將與Heally合作,Heally是一家為替代醫學供應商提供一體化平臺和電子病歷(EMR)/遠程醫療解決方案的公司,將為其KetaDASH患者提供有執照的心理治療師和註冊護士。這種移動解決方案不同於面對面的靜脈治療,也不同於無人監督的遠程醫療模式。

Heally created a platform designed to help alternative medicine clinics address the needs of patients regardless of their location. The platform provides a telehealth and EMR software solution, while concurrently managing lead generation, patient engagement and access to an ecosystem of hundreds of thousands of patients and providers. Ketamine provides an alternative medicine option for those with treatment-resistant depression, post-traumatic stress disorders (PTSD), anxiety, and other mental health conditions. Through the use of Heally's platform, a registered nurse arrives at the patient's preferred location — be it home, office, or hotel — and safely administers a sublingual ketamine lozenge. Together, the patient and nurse, connect to a psychotherapist via Heally's telehealth portal to begin each treatment session.

Heally創建了一個平臺,旨在幫助替代醫學診所滿足患者的需求,無論他們在哪裏。該平臺提供遠程醫療和電子病歷軟件解決方案,同時管理潛在客户、患者參與以及與數十萬患者和提供商組成的生態系統的訪問。氯胺酮為那些患有難治性抑鬱症、創傷後應激障礙(PTSD)、焦慮和其他精神健康問題的人提供了另一種藥物選擇。通過使用Heally的平臺,註冊護士到達患者的首選位置-無論是家、辦公室還是酒店-並安全地給患者注射氯胺酮含片。病人和護士一起,通過Heally的遠程健康門户網站連接到心理治療師,開始每一次治療。

"Heally is the perfect platform to help expand the reach of alternative medicine clinics specifically in the psychedelic treatment space," said Heally CEO Greg Rovner. "Our software solutions provide all the necessary tools alternative medicine clinics need to manage their practice and treat patients online."

Heally首席執行官格雷格·羅夫納(Greg Rovner)説:“Heally是一個完美的平臺,可以幫助擴大替代醫學診所的覆蓋範圍,特別是在迷幻治療領域。”我們的軟件解決方案提供了替代醫學診所管理其業務和在線治療患者所需的所有必要工具。“

Ehave's KetaDASH service provides patients with an in-home setting that offers a space for healing, growth and transformation through psychedelic therapies. Mental health continues to be a national health crisis as rates of anxiety, depression and PTSD keep climbing. The Covid-19 pandemic has impacted the quality of care, access to healthcare providers, and driven a greater demand for mental health professionals than ever before. The World Health Organization says depression is one of the leading causes of disability. Suicide is the second leading cause of death among 15-29-year-olds. People with severe mental health conditions die prematurely – as much as two decades early – due to preventable physical conditions. More than 47 million American workers quit their jobs in 2021, according to the U.S. Bureau of Labor Statistics. 84% of employees reported at least one workplace factor that negatively impacted their mental health, while 50% of employees claimed to leave their jobs for their mental health in 2021.

EHave的KetaDASH服務為患者提供了一個家庭環境,通過迷幻療法為患者的康復、成長和轉變提供了一個空間。隨着焦慮、抑鬱和創傷後應激障礙(PTSD)的發病率不斷攀升,心理健康仍然是一個全國性的健康危機。新冠肺炎大流行影響了醫療質量,影響了醫療保健提供者的提供,並推動了對精神衞生專業人員的需求比以往任何時候都更大。世界衞生組織表示,抑鬱症是導致殘疾的主要原因之一。自殺是15-29歲青少年的第二大死因。由於可預防的身體狀況,患有嚴重精神健康問題的人過早死亡--早死長達20年之久。根據美國勞工統計局(U.S.Bureau of Labor Statistics)的數據,2021年有超過4700萬美國工人辭職。84%的員工報告至少有一個工作場所因素對他們的心理健康產生了負面影響,而50%的員工聲稱2021年為了心理健康而離職。

Ben Kaplan, CEO of Ehave, said, "KetaDASH provides us with the transformative power of our psychedelic-assisted therapy protocols for people struggling with their mental health. KetaDASH is a managed service organization focused on the psychedelic sector that benefits physicians by helping them streamline their practice operations, create new revenue opportunities, and achieve better patient outcomes." Mr. Kaplan continued, "As we continue to grow into new markets, the potential to positively change people's lives is endless. Access to Heally's platform along with its provider network of licensed doctors, psychotherapists, and registered nurses will allow us to expand to those new markets quicker, while offering alternative treatment to those who need it."

EHave的首席執行官本·卡普蘭説:“KetaDASH為我們的迷幻輔助治療方案為精神健康苦苦掙扎的人們提供了變革性的力量。KetaDASH是一家專注於迷幻領域的管理服務組織,通過幫助醫生簡化執業操作,創造新的收入機會,並獲得更好的患者結果,使他們受益。”卡普蘭先生繼續説:“隨着我們不斷進入新市場,積極改變人們生活的潛力是無窮無盡的。進入Heally的平臺及其由有執照的醫生、心理治療師和註冊護士組成的提供者網絡將使我們能夠更快地擴展到這些新市場,同時為需要它的人提供替代治療。”

About Ehave, Inc.

關於eHave,Inc.

Ehave is a leading healthcare services and technology company, focused on progressing psychedelics-to-Therapeutics by engineering novel compounds and new treatment protocols for treating brain health. Together with our network of scientists and mental health professionals, we are on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues, leveraging clinical data to help us achieve optimal patient outcomes. Ehave's operations span across the entire USA, Canada, Jamaica, and Australia. Additional information on Ehave can be found on the Company's website at:

EHave是一家領先的醫療服務和技術公司,專注於通過設計新的化合物和新的治療方案來治療大腦健康,從而推動迷幻藥物到治療藥物的發展。我們與我們的科學家和精神健康專業人員網絡一起,肩負着為患者創造安全有效的治療方法的使命,以解決大量的精神健康問題,利用臨牀數據幫助我們實現最佳的患者結果。EHave的業務遍及整個美國、加拿大、牙買加和澳大利亞。有關eHave的更多信息可在公司網站上找到,網址為:

About Heally

關於Heally

Heally is the only all-in-one platform and EMR/telehealth solution for alternative medicine clinics. Heally brings alternative medicine clinics online and connects patients to licensed physicians in-office or online via telehealth, leveraging HIPAA-compliant encrypted live video and messaging.

Heally是替代醫學診所唯一的一體化平臺和EMR/遠程醫療解決方案。Heally利用符合HIPAA標準的加密實時視頻和消息,將替代醫學診所上線,並通過遠程醫療將患者與辦公室內或在線的執業醫生連接起來。

Forward-Looking Statement Disclaimer

前瞻性聲明免責聲明

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company's research, manufacturing and other development efforts; (ii) the Company's ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company's products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company's industry and introduction of competing products; (vi) the Company's ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading "Risk Factors" in Ehave, Inc.'s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC's website,

本新聞稿包含“1995年私人證券訴訟改革法案”所指的“前瞻性陳述”。此類聲明的前綴可能是“打算”、“可能”、“將”、“計劃”、“預期”、“預期”、“計劃”、“預測”、“估計”、“目標”、“相信”、“希望”、“潛在”或類似的詞語。前瞻性陳述基於某些假設,會受到各種已知和未知的風險和不確定性的影響,其中許多風險和不確定性是公司無法控制的,無法預測或量化,因此,實際結果可能與這些前瞻性陳述中明示或暗示的結果大不相同:(I)公司研究、製造和其他開發工作的發起、時間、進展和結果;(Ii)公司推進其產品成功完成開發和商業化的能力;(Iii)製造、開發、商業化的能力。, (4)缺乏足夠的資金為產品開發和業務運營提供資金;(5)公司所在行業內具有競爭力的公司和技術以及競爭產品的推出;(6)公司建立和維持公司合作的能力;(7)關鍵管理人員的流失;(8)公司能夠建立和維持涵蓋其產品的知識產權的保護範圍以及在不侵犯他人知識產權的情況下運營其業務的能力;(Ix)可能未能遵守適用的健康信息隱私和安全法律以及其他州和聯邦隱私和安全法律;以及(X)難以預測美國FDA及其法規的行動。本新聞稿中包含的所有前瞻性陳述僅在本新聞稿發佈之日作出。除非法律要求,否則公司不承擔更新任何書面或口頭前瞻性陳述的義務。有關公司和可能影響前瞻性陳述實現的風險因素的更多詳細信息,包含在eHave,Inc.於2015年9月24日提交給美國證券交易委員會(美國證券交易委員會)的經修訂的F-1表格註冊説明書中的“風險因素”一欄,該説明書可在美國證券交易委員會網站上查閲。

For Media and Investor Relations, please contact:

如需瞭解媒體和投資者關係,請聯繫:

David L. Kugelman

大衞·L·庫格爾曼

(866) 692-6847 Toll Free - U.S. & Canada

(866)692-6847免費-美國和加拿大

(404) 281-8556 Mobile and WhatsApp

(404)281-8556移動電話和WhatsApp

Email: Ir@Ehave.com

電子郵件:ir@ehave.com

Skype: kugsusa

Skype:kugsusa

LinkedIn: 

LinkedIn:


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論